There are 3158 resources available
195P - Preclinical efficacy of the trastuzumab duocarmazine SYD985 as monotherapy or in combination with the PARP inhibitor niraparib in HER2-expressing endometrial cancer
Presenter: Eva Colas
Session: Poster session 08
196P - Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies
Presenter: Richard Schlenk
Session: Poster session 08
197P - PRIME-ROSE: Merging clinical outcome data from DRUP-like clinical trials
Presenter: Tina Kringelbach
Session: Poster session 08
198P - Inavolisib in cancers with activating PIK3CA mutations: Results from the CRAFT trial
Presenter: Christoph Heilig
Session: Poster session 08
199P - Association of homologous recombination deficiency status with outcomes for ovarian cancer patients treated with olaparib, and exploration of other biomarkers of relapse and survival
Presenter: qingsheng xie
Session: Poster session 08
200P - Outcomes of patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study
Presenter: Tilmann Bochtler
Session: Poster session 08
201P - Efficacy of antibody drug conjugate (ADC) by mRNA expression of targeted genes in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-2
Presenter: Takao Fujisawa
Session: Poster session 08
202P - eIF4E inhibition exhibits anti-tumor activity and re-sensitizes acquired resistant KRAS G12C NSCLC to KRAS inhibitors
Presenter: Andrew Truong
Session: Poster session 09
203P - An innovative evidence-based laboratory medicine (EBLM) test to help doctors in multi-cancer early detection (MCED)
Presenter: Jose D Santotoribio
Session: Poster session 09
204P - Assessing biomarker testing awareness among patients and caregivers in NSCLC through an interdisciplinary global survey
Presenter: Rodrigo Paredes
Session: Poster session 09